Expression of serum AMPD1 in thyroid carcinoma and its clinical significance

Zha,Tianzhou; Wu,Haorong

doi:10.3892/etm.2018.5859

Expression of serum AMPD1 in thyroid carcinoma and its clinical significance

Authors:
- Tianzhou Zha
- Haorong Wu
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: February 12, 2018 https://doi.org/10.3892/etm.2018.5859
Pages: 3357-3361
Copyright: © Zha et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the expression of adenosine monophosphate deaminase 1 (AMPD1) in serum of patients with papillary thyroid carcinoma (PTC) and its clinical significance. The expression levels of AMPD1 mRNA in serum of 157 patients with PTC and 100 normal controls were detected by real-time fluorescent quantitative polymerase chain reaction (PCR), and the relationships between expression level of AMPD1 in serum of PTC patients and clinicopathological factors as well as prognosis were analyzed. The results of real-time fluorescent quantitative PCR showed that the expression of AMPD1 mRNA in serum of PTC patients was lower than that in normal human serum (P<0.01). The expression of AMPD1 in serum of PTC patients was not significantly different from the clinicopathological features such as sex, age, lymph node metastasis and the number of lesions (P>0.05); there were distinct differences between its expression and tumor-node-metastasis (TNM) staging and tumor diameter (P<0.05). The single factor Cox analysis revealed that sex, age, number of lesions, TNM staging and the occurrence of lymph node metastasis were significantly correlated with the prognosis of patients (P<0.05). Multivariate Cox analysis showed that TNM staging hazard ratio (HR)=2.93, 95% confidence interval (CI): 1.52‑7.04, P=0.015 was an independent prognostic factor in PTC patients. Survival analysis indicated that there was a statistically significant difference in the 5-year overall survival rate between patients with high expression of AMPD1 and those with low expression (P=0.007). In conclusion, the expression of AMPD1 in serum of patients with PTC is closely related to the malignant evolution of PTC and clinical prognosis of patients. AMPD1 is expected to become an important molecule in judging the clinical prognosis of PTC patients, and may become a new target for molecular targeted therapy of PTC.

View Figures

View References

1	Valmasoni M, Pierobon ES, Ruol A, De Pasqual CA, Zanchettin G, Moletta L, Salvador R, Costantini M and Merigliano S: Endoscopic tumor length should be reincluded in the esophageal cancer staging system: Analyses of 662 consecutive patients. PLoS One. 11:e01530682016. View Article : Google Scholar : PubMed/NCBI
2	Mazzaferri EL and Young RL: Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 70:511–518. 1981. View Article : Google Scholar : PubMed/NCBI
3	Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR and de la Chapelle A: Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 105:pp. 7269–7274. 2008; View Article : Google Scholar : PubMed/NCBI
4	Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, et al: Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 98:pp. 15044–15049. 2001; View Article : Google Scholar : PubMed/NCBI
5	Hu Y, Wang H, Chen E, Xu Z, Chen B and Lu G: Candidate microRNAs as biomarkers of thyroid carcinoma: A systematic review, meta-analysis, and experimental validation. Cancer Med. 5:2602–2614. 2016. View Article : Google Scholar : PubMed/NCBI
6	Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et al Cancer Genome Atlas Research Network, : Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
7	Fu XM, Guo W, Li N, Liu HZ, Liu J, Qiu SQ, Zhang Q, Wang LC, Li F and Li CL: The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur Rev Med Pharmacol Sci. 21:3239–3246. 2017.PubMed/NCBI
8	Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A and Piana S: Update on anaplastic thyroid carcinoma: Morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014:7908342014. View Article : Google Scholar : PubMed/NCBI
9	Wei WJ, Lu ZW, Wang Y, Zhu YX, Wang YL and Ji QH: Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies. Cancer Genet. 208:68–75. 2015. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, et al: Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 24:2318–2329. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Mo X, Xu Y, Zuo B, Lei M, Li F, Jiang S, Deng C and Xiong Y: Molecular characterization and expression patterns of AMP deaminase1 (AMPD1) in porcine skeletal muscle. Comp Biochem Physiol B Biochem Mol Biol. 151:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
13	Tousoulis D, Kioufis S, Siasos G, Oikonomou E, Zaromitidou M, Maniatis K, Kokkou E, Mazaris S, Zakynthinos G, Konsola T, et al: The impact of AMPD1 gene polymorphism on vascular function and inflammation in patients with coronary artery disease. Int J Cardiol. 172:e516–e518. 2014. View Article : Google Scholar : PubMed/NCBI
14	Sabina RL, Morisaki T, Clarke P, Eddy R, Shows TB, Morton CC and Holmes EW: Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem. 265:9423–9433. 1990.PubMed/NCBI
15	Fischer S, Drenckhahn C, Wolf C, Eschrich K, Kellermann S, Froster UG and Schober R: Clinical significance and neuropathology of primary MADD in C34-T and G468-T mutations of the AMPD1 gene. Clin Neuropathol. 24:77–85. 2005.PubMed/NCBI
16	Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL and Holmes EW: Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 99:1422–1425. 1999. View Article : Google Scholar : PubMed/NCBI
17	Li J, Yang T, Zhao T, Liang J and Lin YS: Clinical outcome of radioiodine therapy in low-intermediate risk papillary thyroid carcinoma with BRAF(V600E) mutation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 38:346–350. 2016.(In Chinese). PubMed/NCBI
18	Cheng J, Morisaki H, Toyama K, Sugimoto N, Shintani T, Tandelilin A, Hirase T, Holmes EW and Morisaki T: AMPD1: A novel therapeutic target for reversing insulin resistance. BMC Endocr Disord. 14:962014. View Article : Google Scholar : PubMed/NCBI
19	Feng AF, Liu ZH, Zhou SL, Zhao SY, Zhu YX and Wang HX: Effects of AMPD1 gene C34T polymorphism on cardiac index, blood pressure and prognosis in patients with cardiovascular diseases: A meta-analysis. BMC Cardiovasc Disord. 17:1742017. View Article : Google Scholar : PubMed/NCBI
20	Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR and Grant CS: Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 114:1050–1058. 1993.PubMed/NCBI